Skip to content
Sign in
Health · North America

Kennedy sets enforcement policy for six peptides despite FDA safety concerns

Health Secretary Robert F. Kennedy Jr. set an enforcement policy covering six peptide substances, despite FDA scientists’ concerns about the evidence and safety. The scientists say evidence is insufficient to determine whether the peptides work and warn they may be dangerous.

AI-assisted synthesis · Based on 2 outlets' reporting · Article text read from 1 of 2 outletsHow it's made

View timeline · 6 entries
2 outletsLatest reporting 3 min read
Coverage: Too few ratedL 0 · C 1 · R 0 · 1 unrated
Updat3 graphic: North America
Updat3 graphic · Map data: Natural Earth Natural Earth (public domain)

What happened

Key facts

  • FDA scientists say the evidence is insufficient to show whether the peptides are effective and warn they may be dangerous (per Ars Technica).
  • In 2023, safety concerns led the FDA to remove the six peptides from a list of drugs that could be made by compounding pharmacies (per Ars Technica).
  • The rule is titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” (per Ars Technica).
  • Kennedy said he uses some of the peptides and called himself a “big fan.” (per Ars Technica).
  • Fred Mills, chief policy officer of Americans for Safe and Effective Medicines, said the policy does not resolve concerns about untested products, safety risks, questionable ingredients or misleading claims (per Ars Technica).

The brief

Health Secretary Robert F. Kennedy Jr. set an enforcement discretion policy covering six peptide substances, although FDA scientists say the evidence is insufficient to establish whether they are effective and warn the substances may be dangerous. Ars Technica reported that the policy concerns BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.

The rule is titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” Ars Technica says it was made available on the Federal Register and describes the policy as addressing enforcement involving these peptide bulk drug substances.

The rule’s title refers to 503A compounding; the article describes compounding pharmacies as making customized drug formulations for patients and, in some cases, producing specialty drugs in bulk. The policy follows an earlier FDA action. In 2023, safety concerns led the agency to remove the six peptides from a list of drugs that compounding pharmacies could make.

The FDA scientists’ current concerns, as reported by Ars Technica, are twofold: the available evidence does not establish whether the peptides work, and the substances may pose dangers. The account does not identify specific adverse events or provide study results.

Kennedy said he uses some of the peptides and described himself as a “big fan.” Ars Technica also reports that the Department of Health and Human Services posted an explanation of the policy that included more of Kennedy’s rationale for easing enforcement of the six substances.

His statement about personal use and his view are distinct from the FDA scientists’ assessment of the evidence and safety. Fred Mills, chief policy officer of Americans for Safe and Effective Medicines, criticized the policy in a statement. Mills said it does not resolve concerns about untested products, safety risks, questionable ingredients or misleading claims.

His remarks identify issues he says remain unresolved; the article does not provide additional detail on the products or claims he referenced. The Federal Register notice set October 30 as the date for final publication. The policy’s stated scope, the named compounds, the FDA scientists’ concerns and Mills’s criticism are the specific points described in the account.

HHS’s separate headline says Kennedy is bringing his “Take Back Your Health Tour” to Texas and Florida, but does not state that the tour is connected to the peptide policy.

Why it matters

  • The FDA scientists’ stated concern is that evidence does not establish whether the six named peptides work, while they warn the substances may be dangerous.
  • The enforcement policy covers six substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
  • Compounding pharmacies had been barred from making the six peptides after the FDA removed them from its list in 2023 over safety concerns.
  • Mills of Americans for Safe and Effective Medicines says the policy leaves concerns about untested products, safety risks, questionable ingredients and misleading claims unresolved.

What to watch next

  • Whether the Federal Register publishes the final rule on October 30, the date specified in the notice.
  • Whether HHS provides further explanation of its policy on the six named peptide substances.
  • Whether FDA scientists’ concerns about efficacy evidence and potential danger are addressed in the final publication.

How it's being covered

Coverage analysisShow details
2 source articles · 2 unique outlets
Outlet political mix: Too few rated· 1 Center · 1 unrated
Where the outlets are based: US/Canada 50% · Unknown 50%
Outlet political mix
Too few rated
Left
Center
Right
0 outlets
1 outlet
0 outlets
The marker shows coverage balance: each unique outlet counts once. 1 unrated outlet is not included.
Geography
Where the outlets covering this story are based.
2 unique outletsDominant coverage: US/Canada
Limited coverage
  • Coverage is currently limited to 2 outlets.
How we measure coverage

How outlets' accounts compare

Updat3 does not yet have enough full reports to compare how outlets framed this story.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. President Franklin D. Roosevelt signed the Federal Food, Drug, and Cosmetic Act, expanding federal oversight of food, drugs and cosmetics.
    Background · compiled and fact-checked by Updat3
  2. President John F. Kennedy signed the Kefauver-Harris Amendments, requiring evidence of drug effectiveness as well as safety.
    Background · compiled and fact-checked by Updat3
  3. In 2002, the Supreme Court struck down parts of that law’s advertising restrictions in *Thompson v. Western States Medical Center*, while leaving the compounding framework in place.
    Background · from our historical context
  4. President Barack Obama signed the Drug Quality and Security Act, setting rules for bulk substances used in section 503A compounding.
    Background · compiled and fact-checked by Updat3
  5. The FDA placed six peptide bulk drug substances in a category for substances raising significant safety concerns.
    Background · compiled and fact-checked by Updat3
  6. The Senate confirmed Robert F. Kennedy Jr. as secretary of Health and Human Services.
    Background · compiled and fact-checked by Updat3

How we got here

The immediate backdrop was the FDA’s 2023 decision to place six peptide bulk drug substances in a category for substances that raised significant safety concerns, making them ineligible for routine compounding under the agency’s interim policy. The rules governing those pharmacies trace to the Federal Food, Drug, and Cosmetic Act.

The 1997 Food and Drug Administration Modernization Act added section 503A, setting conditions under which a pharmacist or physician could compound drugs for individual patients without the drugs being treated as unapproved new drugs. In 2002, the Supreme Court struck down parts of that law’s advertising restrictions in *Thompson v.

Original sources

2 articles from 2 outlets

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.